Description
Market Report Coverage – Somatic Genetic Testing
Market Segmentation
• Product Type – Products (Kits and Assays, Instruments, and Software) and Services
• Sample– Tissue-Based, Blood-Based, Bone Marrow Aspirates, and Others
• Technology – Sequencing (NGS and Traditional Sequencing), Polymerase Chain Reaction (RT-PCR and dPCR), Microarray, and Other Technologies
• Application – Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors), and Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)
• End User – Academic and Research Institutions, Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Other End Users
Regional Segmentation
• North America – U.S., and Canada
• Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World
Growth Drivers
• Global Increase in Cancer Prevalence
• Increasing Consumer Awareness for Tailored Cancer Therapy
• Decreasing Cost of Sequencing
• Increasing Adoption of Inorganic Growth Strategies in the Market
Market Challenges
• Uncertain Regulatory and Reimbursement Policies
• Lack of Trained Professionals in the Field of Oncology
• Lack of Established Treatment Protocols for High-Valued Cancer Tests in Emerging Economies
Market Opportunities
• Technological Advancements in the Field of Cancer Genomics
• Massive Scope for Adoption of NGS-based Somatic Genetic Testing in the Emerging Markets
Key Companies Profiled
Agilent Technologies, Inc., ARUP Laboratories, ASURAGEN INC., Beijing Genomics Institute (BGI) Genomics Co., Ltd, bioMérieux S.A., CENTOGENE N.V, CIRCULOGENE Theranostics, LLC, F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Mission Bio, NeoGenomics Laboratories, Inc., OmniSeq, Oxford Nanopore Technologies, Ltd., Pacific Biosciences of California, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, and Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
• How is somatic genetic testing revolutionizing the field of cancer diagnostics?
• What are the major market drivers, challenges, and opportunities in the global somatic genetic testing market?
• What are the underlying structures resulting in the emerging trends within the global somatic genetic testing market?
• How did the COVID-19 pandemic impact the global somatic genetic testing landscape?
• What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to somatic genetic testing?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter in a particular region?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2030 and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Product Type (Products and Services)
o Sample (Tissue-Based, Blood-Based, Bone Marrow Aspirates, and Others)
o Technology (Sequencing, PCR, Microarray, and Others)
o Application (Solid Tumors and Hematological Malignancies)
o End User (Academic and Research Institutions, Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Others)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global somatic genetic testing market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current unmet needs that are being faced?
Market Overview
Our healthcare experts have found somatic genetic testing industry to be one of the most rapidly evolving and dynamic markets and the global market for somatic genetic testing is predicted to grow at a CAGR of 9.30% over the forecast period of 2020-2030. The market is driven by certain factors, which include, global increase in cancer prevalence, increasing consumer awareness for tailored cancer therapies, decreasing cost of sequencing, and increasing adoption of inorganic growth strategies in the market.
The market is favored by the developments in the field of cancer genomics and its attributes such as somatic mutation analysis. The global somatic genetic testing is witnessing significant growth due to the increase in cancer prevalence, increasing consumer awareness for tailored cancer therapy, decreasing cost of sequencing, and increasing adoption of inorganic growth strategies in the market. Additionally, rapid adoption of sequencing instruments by the researchers to conduct cancer genomic research and increasing emphasis on precision medicine are some of the critical factors, which are expected to bolster the market growth.
Furthermore, biotechnology companies are focusing on the development of robust somatic genetic testing solutions for a wide range of applications to support clinicians for conducting in-depth somatic mutation analysis.
Within the research report, the market is segmented on the basis of product type, sample, technology, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies, compelling them to further invest in the development of cancer diagnostic solutions for somatic mutation analysis, thereby aiding clinicians to offer precision therapeutics for cancer treatment. Due to the presence of a diverse product portfolio and intense market penetration, Thermo Fisher Scientific Inc. has been a pioneer in this field and has been a significant competitor in this market.
On the basis of region, North America holds the largest share of the somatic genetic testing market due to high infusion of funding from the government organizations for conducting cancer research, growing prevalence of cancer, rising awareness about precision medicine, and increasing awareness about early cancer detection, among others. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.
Table of Contents
Executive Summary
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Somatic Genetic Testing Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Market Footprint and Growth Potential, $Million, 2019-2030
4.3 Commercialized Assays and Applications
4.4 COVID-19 Impact: Global Somatic Genetic Testing Market
5 Industry Insights
5.1 Overview
5.2 Legal Requirements and Framework in U.S.
5.2.1 FDA Regulation
5.2.2 CMS Regulation
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirements and Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
5.5 Reimbursement Analysis
6 Market Dynamics
6.1 Overview
6.2 Iceberg Analysis
6.3 Impact Analysis
6.4 Market Drivers
6.4.1 Global Increase in Cancer Prevalence
6.4.2 Increasing Consumer Awareness for Tailored Cancer Therapy
6.4.3 Decreasing Cost of Sequencing
6.4.4 Increasing Adoption of Inorganic Growth Strategies in the Market
6.5 Market Restraints
6.5.1 Uncertain Reimbursement and Regulatory Policies
6.5.2 Lack of Trained Professionals in the Field of Oncology
6.5.3 Lack of Established Treatment Protocols for High-Valued Cancer Tests in Emerging Economies
6.6 Market Opportunities
6.6.1 Technological Advancements in the Field of Cancer Genomics
6.6.2 Massive Scope for Adoption of NGS-based Somatic Genetic Tests in Emerging Markets
7 Competitive Landscape
7.1 Product Launches and Upgradations
7.2 Product Approvals
7.3 Synergistic Activities
7.4 Acquisitions
7.5 Market Share Analysis, by Company, 2018–2019
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Company)
7.6.2 Growth Share Analysis (by Technology)
8 Global Somatic Genetic Testing Market (by Product Type), $Million, 2019-2030
8.1 Overview
8.2 Products
8.2.1 Kits and Assays
8.2.2 Instruments
8.2.3 Software
8.3 Services
9 Global Somatic Genetic Testing Market (by Sample), $Million, 2019-2030
9.1 Overview
9.2 Tissue-Based
9.3 Blood-Based
9.4 Bone Marrow Aspirates
9.5 Other Samples
10 Global Somatic Genetic Testing Market (by Technology), $Million, 2019-2030
10.1 Overview
10.2 Sequencing
10.2.1 Next-Generation Sequencing (NGS)
10.2.1.1 Sequencing by Synthesis
10.2.1.2 Other Next-Generation Sequencing Technologies
10.2.2 Traditional Sequencing
10.3 Polymerase Chain Reaction (PCR)
10.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)
10.3.2 Digital Polymerase Chain Reaction (dPCR)
10.4 Microarray
10.5 Other Technologies
11 Global Somatic Genetic Testing Market (by Application), $Million, 2019-2030
11.1 Overview
11.2 Solid Tumors
11.2.1 Breast Cancer
11.2.2 Prostate Cancer
11.2.3 Colorectal Cancer (CRC)
11.2.4 Lung Cancer
11.2.5 Liver Cancer
11.2.6 Ovarian Cancer
11.2.7 Other Solid Tumors
11.3 Hematological Malignancies
11.3.1 Leukemia
11.3.2 Lymphoma
11.3.3 Myeloma
12 Global Somatic Genetic Testing Market (by End User), $Million, 2019-2030
12.1 Overview
12.2 Academic and Research Institutions
12.3 Hospitals and Diagnostic Laboratories
12.4 Pharmaceutical and Biotechnology Companies
12.5 Contract Research Organizations (CROs)
12.6 Other End Users
13 Global Somatic Genetic Testing Market (by Region), $Million, 2019-2030
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.2.3 North America Somatic Genetic Testing Market (by Application), 2019-2030
13.3 Europe
13.3.1 Germany
13.3.2 U.K.
13.3.3 France
13.3.4 Italy
13.3.5 Spain
13.3.6 Netherlands
13.3.7 Rest-of-Europe
13.3.8 Europe Somatic Genetic Testing Market (by Application), 2019-2030
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 South Korea
13.4.6 Rest-of-Asia-Pacific
13.4.7 Asia-Pacific Somatic Genetic Testing Market (by Application), 2019-2030
13.5 Latin America
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest-of-Latin America
13.5.4 Latin America Somatic Genetic Testing Market (by Application), 2019–2030
13.6 Rest-of-the-World (RoW)
14 Company Profiles
14.1 Overview
14.2 Agilent Technologies, Inc.
14.2.1 Company Overview
14.2.2 Role of Agilent Technologies, Inc. in the Global Somatic Genetic Testing Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 ARUP Laboratories
14.3.1 Company Overview
14.3.2 Role of ARUP Laboratories in the Global Somatic Genetic Testing Market
14.3.3 SWOT Analysis
14.4 ASURAGEN Inc.
14.4.1 Company Overview
14.4.2 Role of ASURAGEN Inc. in the Global Somatic Genetic Testing Market
14.4.3 SWOT Analysis
14.5 Beijing Genomics Institute (BGI) Genomics Co., Ltd
14.5.1 Company Overview
14.5.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Somatic Genetic Testing Market
14.5.3 SWOT Analysis
14.6 bioMérieux S.A.
14.6.1 Company Overview
14.6.2 Role of bioMérieux S.A. in the Global Somatic Genetic Testing Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 CENTOGENE N.V.
14.7.1 Company Overview
14.7.2 Role of CENTOGENE N.V. in the Global Somatic Genetic Testing Market
14.7.3 Financials
14.7.4 Key Insights About Financial Health of the Company
14.7.5 SWOT Analysis
14.8 CIRCULOGENE Theranostics, LLC
14.8.1 Company Overview
14.8.2 Role of CIRCULOGENE Theranostics, LLC in the Global Somatic Genetic Testing Market
14.8.3 SWOT Analysis
14.9 F. Hoffmann-La Roche Ltd.
14.9.1 Company Overview
14.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Somatic Genetic Testing Market
14.9.3 Financials
14.9.4 Key Insights About Financial Health of the Company
14.9.5 SWOT Analysis
14.1 Guardant Health, Inc.
14.10.1 Company Overview
14.10.2 Role of Guardant Health, Inc. in the Global Somatic Genetic Testing Market
14.10.3 Financials
14.10.4 SWOT Analysis
14.11 Illumina, Inc.
14.11.1 Company Overview
14.11.2 Role of Illumina, Inc. in the Global Somatic Genetic Testing Market
14.11.3 Financials
14.11.4 Key Insights About Financial Health of the Company
14.11.5 SWOT Analysis
14.12 Invivoscribe, Inc.
14.12.1 Company Overview
14.12.2 Role of Invivoscribe, Inc. in the Global Somatic Genetic Testing Market
14.12.3 SWOT Analysis
14.13 Laboratory Corporation of America Holdings
14.13.1 Company Overview
14.13.2 Role of Laboratory Corporation of America Holdings in the Global Somatic Genetic Testing Market
14.13.3 Financials
14.13.4 SWOT Analysis
14.14 Mission Bio
14.14.1 Company Overview
14.14.2 Role of Mission Bio in the Global Somatic Genetic Testing Market
14.14.3 SWOT Analysis
14.15 NeoGenomics Laboratories, Inc.
14.15.1 Company Overview
14.15.2 Role of NeoGenomics Laboratories, Inc. in the Global Somatic Genetic Testing Market
14.15.3 Financials
14.15.4 Key Insights about Financial Health of the Company
14.15.5 SWOT Analysis
14.16 OmniSeq
14.16.1 Company Overview
14.16.2 Role of Omniseq in the Global Somatic Genetic Testing Market
14.16.3 SWOT Analysis
14.17 Oxford Nanopore Technologies Ltd.
14.17.1 Company Overview
14.17.2 Role of Oxford Nanopore Technologies Ltd. in the Global Somatic Genetic Testing Market
14.17.3 SWOT Analysis
14.18 Pacific Biosciences of California, Inc.
14.18.1 Company Overview
14.18.2 Role of Pacific Biosciences of California, Inc. in the Global Somatic Genetic Testing Market
14.18.3 Financials
14.18.4 Key Insights About Financial Health of the Company
14.18.5 SWOT Analysis
14.19 QIAGEN N.V.
14.19.1 Company Overview
14.19.2 Role of QIAGEN N.V. in the Global Somatic Genetic Testing Market
14.19.3 Financials
14.19.4 Key Insights about Financial Health of the Company
14.19.5 SWOT Analysis
14.2 Quest Diagnostics Incorporated
14.20.1 Company Overview
14.20.2 Role of Quest Diagnostics Incorporated in the Global Somatic Genetic Testing Market
14.20.3 Financials
14.20.4 SWOT Analysis
14.21 Thermo Fisher Scientific Inc.
14.21.1 Company Overview
14.21.2 Role of Thermo Fisher Scientific Inc. in the Global Somatic Genetic Testing Market
14.21.3 Financials
14.21.4 Key Insights about Financial Health of the Company
14.21.5 SWOT Analysis
List of Tables
Table 4.1: Key Somatic Genetic Testing Assays
Table 5.1: Key Coverage Providers for Somatic Genetic Testing
Table 6.1: Likert Scale
Table 6.2: Impact Analysis of Market Drivers
Table 6.3: Impact Analysis of Market Restraints
Table 8.1: Kits and Assays Offered by Key Players
Table 8.2: Instruments Offered by Key Players
Table 8.3: Software Offered by Key Players
Table 8.4: Services Offered by Key Players
Table 11.1: Somatic Genetic Testing Products for Breast Cancer
Table 11.2: Somatic Genetic Testing Products for Breast Cancer
Table 11.3: Somatic Genetic Testing Products for Prostate Cancer
Table 11.4: Somatic Genetic Testing Products for Breast Cancer
Table 11.5: Somatic Genetic Testing Products for Colorectal Cancer
Table 11.6: Somatic Genetic Testing Products for Colorectal Cancer
Table 11.7: Somatic Genetic Testing Products for Lung Cancer
Table 11.8: Somatic Genetic Testing Products for Lung Cancer
Table 11.9: Somatic Genetic Testing Products for Liver Cancer
Table 11.10: Somatic Genetic Testing Products for Liver Cancer
Table 11.11: Somatic Genetic Testing Products for Ovarian Cancer
Table 11.12: Somatic Genetic Testing Products for Ovarian Cancer
Table 11.13: Somatic Genetic Testing Products for Leukemia
Table 11.14: Somatic Genetic Testing Products for Leukemia
Table 11.15: Somatic Genetic Testing Products for Lymphoma
Table 11.16: Somatic Genetic Testing Products for Lymphoma
List of Figures
Figure 1: National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year, 2013-2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Somatic Genetic Testing Market
Figure 3: Global Somatic Genetic Testing Market (by Product Type), $Million, 2019 Vs. 2030
Figure 4: Global Somatic Genetic Testing Market (by Sample), $Million, 2019 Vs. 2030
Figure 5: Global Somatic Genetic Testing Market (by Technology), $Million, 2019 vs. 2030
Figure 6: Global Somatic Genetic Testing Market (by Application), $Million, 2019 vs. 2030
Figure 7: Global Somatic Genetic Testing Market (by End User), $Million, 2019 vs. 2030
Figure 8: Global Somatic Genetic Testing: Market Snapshot
Figure 2.1: Global Somatic Genetic Testing, Market Segmentation
Figure 3.1: Global Somatic Genetic Testing Market: Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Somatic Genetic Testing Market, $Million, 2019-2030
Figure 4.2: Global Somatic Genetic Testing Market: COVID-19 Impact
Figure 6.1: Iceberg Analysis – Global Somatic Genetic Testing Market
Figure 6.2: Global Cancer Burden, 2018
Figure 6.3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 6.4: Synergistic Activities, FY2019-FY2020
Figure 7.1: Share of Key Developments and Strategies, January 2018–December 2020
Figure 7.2: Share of Product Launched and Upgradations (by Company), January 2018–December 2020
Figure 7.3: Share of Product Approvals (by Company), January 2018-December 2020
Figure 7.4: Share of Synergistic Activities (by Company), January 2018- December 2020
Figure 7.5: Share of Acquisitions (by Company), January 2018-December 2020
Figure 7.6: Market Share Analysis for Global Somatic Genetic Testing Market, 2018 and 2019
Figure 7.7: Growth Share Analysis for Global Somatic Genetic Testing Market (by Company), 2019
Figure 7.8: Growth Share Analysis for Global Somatic Genetic Testing Market (by Technology), 2019-2030
Figure 8.1: Global Somatic Genetic Testing Market (by Product Type)
Figure 8.2: Global Somatic Genetic Testing Market (by Product Type), 2019-2030
Figure 8.3: Global Somatic Genetic Testing Market (by Product), $Million, 2019-2030
Figure 8.4: Global Somatic Genetic Testing Market (by Products), 2019 and 2030
Figure 8.5: Global Somatic Genetic Testing Market (Kits and Assays), $Million, 2019-2030
Figure 8.6: Global Somatic Genetic Testing Market (Instruments), $Million, 2019-2030
Figure 8.7: Global Somatic Genetic Testing Market (Software), $Million, 2019-2030
Figure 8.8: Global Somatic Genetic Testing Market (Services), $Million, 2019-2030
Figure 9.1: Global Somatic Genetic Testing Market (by Sample), $Million, 2019-2030
Figure 9.2: Global Somatic Genetic Testing Market (by Sample), 2019 and 2030
Figure 9.3: Global Somatic Genetic Testing Market (Tissue-Based), $Million, 2019-2030
Figure 9.4: Global Somatic Genetic Testing Market (Blood-Based), $Million, 2019-2030
Figure 9.5: Global Somatic Genetic Testing Market (Bone Marrow Aspirates), $Million, 2019-2030
Figure 9.6: Global Somatic Genetic Testing Market (Other Samples), $Million, 2019-2030
Figure 10.1: Global Somatic Genetic Testing Market (by Technology)
Figure 10.2: Global Somatic Genetic Testing Market (by Technology), 2019 and 2030
Figure 10.3: Global Somatic Genetic Testing Market (by Sequencing), $Million, 2019-2030
Figure 10.4: Global Somatic Genetic Testing Market (by Sequencing), 2019 and 2030
Figure 10.5: Global Somatic Genetic Testing Market (by NGS), $Million, 2019-2030
Figure 10.6: Global Somatic Genetic Testing Market (by NGS), 2019 and 2030
Figure 10.7: Global Somatic Genetic Testing Market (SBS), $Million, 2019-2030
Figure 10.8: Global Somatic Genetic Testing Market (Other Next-Generation Sequencing Technologies), $Million, 2019-2030
Figure 10.9: Global Somatic Genetic Testing Market (Traditional Sequencing), $Million, 2019-2030
Figure 10.10: Global Somatic Genetic Testing Market (by PCR), $Million, 2019-2030
Figure 10.11: Global Somatic Genetic Testing Market (by PCR), 2019 and 2030
Figure 10.12: Global Somatic Genetic Testing Market (RT-PCR), $Million, 2019-2030
Figure 10.13: Global Somatic Genetic Testing Market (dPCR), $Million, 2019-2030
Figure 10.14: Global Somatic Genetic Testing Market (Microarray), $Million, 2019-2030
Figure 10.15: Global Somatic Genetic Testing Market (Other Technologies), $Million, 2019-2030
Figure 11.1: Global Somatic Genetic Testing Market (by Application)
Figure 11.2: Global Somatic Genetic Testing Market (by Application), $Million, 2019-2030
Figure 11.3: Global Somatic Genetic Testing Market (by Solid Tumors), $Million, 2019-2030
Figure 11.3: Global Somatic Genetic Testing Market (by Solid Tumors), 2019 and 2030
Figure 11.4: Global Prevalence of Breast Cancer, (2014–2019)
Figure 11.5: Global Somatic Genetic Testing Market (Breast Cancer), $Million, 2019-2030
Figure 11.6: Global Prevalence of Prostate Cancer, (2014-2019)
Figure 11.7: Global Somatic Genetic Testing Market (Prostate Cancer), $Million, 2019-2030
Figure 11.8: Global Prevalence of Colorectal Cancer (2014-2019)
Figure 11.9: Global Somatic Genetic Testing Market (Colorectal Cancer), $Million, 2019-2030
Figure 11.10: Global Prevalence of Lung Cancer (2014-2019)
Figure 11.11: Global Somatic Genetic Testing Market (Lung Cancer), $Million, 2019-2030
Figure 11.12: Global Prevalence of Liver Cancer (2014-2019)
Figure 11.13: Global Somatic Genetic Testing Market (Liver Cancer), $Million, 2019-2030
Figure 11.14: Global Prevalence of Ovarian Cancer (2014-2019)
Figure 11.15: Global Somatic Genetic Testing Market (Ovarian Cancer), $Million, 2019-2030
Figure 11.16: Global Somatic Genetic Testing Market (Other Solid Tumors), $Million, 2019-2030
Figure 11.17: Global Somatic Genetic Testing Market (by Hematological Malignancies), $Million, 2019-2030
Figure 11.18: Global Somatic Genetic Testing Market (by Hematological Malignancies), 2019 and 2030
Figure 11.19: Global Prevalence of Leukemia, (2014-2019)
Figure 11.20: Global Somatic Genetic Testing Market (Leukemia), $Million, 2019-2030
Figure 11.21: Global Prevalence of Lymphoma (2014-2019)
Figure 11.22: Global Somatic Genetic Testing Market (Lymphoma), $Million, 2019-2030
Figure 11.23: Global Prevalence of Myeloma (2014-2019)
Figure 11.24: Global Somatic Genetic Testing Market (Myeloma), $Million, 2019-2030
Figure 12.1: Global Somatic Genetic Testing Market (by End User)
Figure 12.2: Global Somatic Genetic Testing Market (by End User), $Million, 2019-2030
Figure 12.3: Global Somatic Genetic Testing Market (Academic and Research Institutions), $Million, 2019-2030
Figure 12.4: Global Somatic Genetic Testing Market (Hospitals and Diagnostic Laboratories), $Million, 2019-2030
Figure 12.5: Global Somatic Genetic Testing Market (Pharmaceutical and Biotechnology Companies), $Million, 2019-2030
Figure 12.6: Global Somatic Genetic Testing Market (Contract Research Organizations), $Million, 2019-2030
Figure 12.7: Global Somatic Genetic Testing Market (Other End Users), $Million, 2019-2030
Figure 13.1: Global Somatic Genetic Testing Market (by Region)
Figure 13.2: Global Somatic Genetic Testing Market (by Region), $Million, 2019-2030
Figure 13.3: Global Somatic Genetic Testing Market (by Region), 2019-2030
Figure 13.4: North America Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.5: North America: Market Dynamics
Figure 13.6: North America Somatic Genetic Testing Market (by Country), $Million, 2019-2030
Figure 13.7: U.S. Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.8: Canada Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.9: Growth-Share Analysis for North America Somatic Genetic Testing Market (by Application), 2019-2030
Figure 13.10: Europe Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.11: Europe: Market Dynamics
Figure 13.12: Europe Somatic Genetic Testing Market (by Country), $Million, 2019-2030
Figure 13.13: Germany Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.14: U.K. Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.15: France Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.16: Italy Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.17: Spain Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.18: Netherlands Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.19: Rest-of-Europe Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.20: Growth-Share Analysis for Europe Somatic Genetic Testing Market (by Application), 2019-2030
Figure 13.21: Asia-Pacific Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.22: APAC: Market Dynamics
Figure 13.23: APAC Somatic Genetic Testing Market (by Country), $Million, 2019-2030
Figure 13.24: China Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.25: Japan Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.26: India Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.27: Australia Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.28: South Korea Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.29: RoAPAC Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.30: Growth-Share Analysis for Asia-Pacific Somatic Genetic Testing Market (by Application), 2019-2030
Figure 13.31: Latin America Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.32: Latin America: Market Dynamics
Figure 13.33: Latin America Somatic Genetic Testing Market (by Country), $Million, 2019-2030
Figure 13.34: Brazil Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.35: Mexico Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.36: Rest-of-Latin America Somatic Genetic Testing Market, $Million, 2019-2030
Figure 13.37: Growth-Share Analysis for Latin America Somatic Genetic Testing Market (by Application), 2019-2030
Figure 13.38: RoW Somatic Genetic Testing Market, $Million, 2019-2030
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Agilent Technologies, Inc.: Product Portfolio
Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.8: ARUP Laboratories: Product Portfolio
Figure 14.9: ARUP Laboratories: SWOT Analysis
Figure: ASURAGEN, Inc.: Product Portfolio
Figure 14.10: ASURAGEN, Inc.: SWOT Analysis
Figure 14.11: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Product Portfolio
Figure 14.12: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT Analysis
Figure 14.13: bioMérieux S.A.: Product Portfolio
Figure 14.14: bioMérieux S.A.: Overall Financials, 2017-2019
Figure 14.15: bioMérieux S.A.: Revenue (by Segment), 2017-2019
Figure 14.16: bioMérieux S.A.: Revenue (by Region), 2017-2019
Figure 14.17: bioMérieux S.A.: R&D Expenditure, 2017-2019
Figure 14.18: bioMérieux S.A.: SWOT Analysis
Figure 14.19: CENTOGENE N.V.: Portfolio
Figure 14.20: CENTOGENE N.V.: Overall Financials, 2018-2020
Figure 14.21: CENTOGENE N.V.: Sales (by Segment), 2017-2019
Figure 14.22: CENTOGENE N.V.: Revenue (by Region), 2017-2019
Figure 14.23: CENTOGENE N.V.: R&D Expenditure, 2017-2019
Figure 14.24: CENTOGENE N.V.: SWOT Analysis
Figure 14.25: CIRCULOGENE Theranostics, LLC: Portfolio
Figure 14.26: CIRCULOGENE Theranostics, LLC: SWOT Analysis
Figure 14.27: F. Hoffmann-La Roche Ltd.: Portfolio
Figure 14.28: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020
Figure 14.29: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2018-2020
Figure 14.30: F. Hoffmann-La Roche Ltd.: Sales (by Diagnostics), 2018-2020
Figure 14.31: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
Figure 14.32: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
Figure 14.33: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 14.34: Guardant Health, Inc.: Portfolio
Figure 14.35: Guardant Health, Inc.: Overall Financials, 2017-2019
Figure 14.36: Guardant Health, Inc.: Revenue (by Segment), 2017-2019
Figure 14.37: Guardant Health, Inc.: Revenue (by Region), 2017-2019
Figure 14.38: Guardant Health, Inc.: SWOT Analysis
Figure 14.39: Illumina, Inc.: Product Portfolio
Figure 14.40: Illumina, Inc.: Overall Financials, 2017-2019
Figure 14.41: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 14.42: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 14.43: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 14.44: Illumina, Inc.: SWOT Analysis
Figure 14.45: Invivoscibe, Inc.: Product Portfolio
Figure 14.46: Invivoscibe, Inc.: SWOT Analysis
Figure 14.47: Laboratory Corporation of America Holdings: Product Portfolio
Figure 14.48: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 14.49: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 14.50: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 14.51: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.52: Mission Bio: Product Portfolio
Figure 14.53: Mission Bio: SWOT Analysis
Figure 14.54: NeoGenomics Laboratories, Inc.: Portfolio
Figure 14.55: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 14.56: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 14.57: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 14.58: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 14.59: OmniSeq: Portfolio
Figure 14.60: OmniSeq: SWOT Analysis
Figure 14.61: Oxford Nanopore Technologies Ltd.: Product Portfolio
Figure 14.62: Oxford Nanopore Technologies Ltd..: SWOT Analysis
Figure 14.63: Pacific Biosciences of California, Inc.: Product Portfolio
Figure 14.64: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 14.65: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 14.66: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 14.67: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 14.68: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 14.69: QIAGEN N.V.: Product Portfolio
Figure 14.70: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 14.71: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 14.72: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 14.73: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 14.74: QIAGEN N.V.: SWOT Analysis
Figure 14.75: Quest Diagnostics Incorporated: Portfolio
Figure 14.76: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 14.77: Quest Diagnostics Incorporated: Revenue (by Segment), 2017-2019
Figure 14.78: Quest Diagnostics Incorporated: SWOT Analysis
Figure 14.79: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 14.80: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
Figure 14.81: Thermo Fisher Scientific Inc.: Sales (by Segment): 2017-2020
Figure 14.82: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 14.83: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 14.84: Thermo Fisher Scientific Inc.: SWOT Analysis
Reviews
There are no reviews yet.